CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleRevenue is $522,658, lower than 95% of all stocks globally
- PositionGross margin is 100%, higher than 95% of its Biotechnology peers (median 67.1%)
- Interpretations5 currently firing — 5
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
496.03BKRW357.42M · vs all stocks (USD)
Revenue (TTM)
725.35MKRW522.66K · vs all stocks (USD)
Profit Margin
0.00%vs Biotechnology peers
Beta
1.66xvs all stocks
52-Week Change
0.95%vs all stocks
Market Capitalization
496.03BKRW357.42M · vs all stocks (USD)
Enterprise Value
530.98BKRW382.60M · vs all stocks (USD)
Forward P/E
-22.25xvs Biotechnology peers
Price to Book (MRQ)
5.06xvs Biotechnology peers
Enterprise to Revenue
732.03xvs Biotechnology peers
Enterprise to EBITDA
-61.22xvs Biotechnology peers
Gross Margin
100.00%vs Biotechnology peers
Profit Margin
0.00%vs Biotechnology peers
Operating Margin
-302.30%vs Biotechnology peers
Return on Assets (TTM)
-5.85%vs Biotechnology peers
Return on Equity (TTM)
-10.64%vs Biotechnology peers
Revenue (TTM)
725.35MKRW522.66K · vs all stocks (USD)
Revenue per Share (TTM)
31.84KRWUpdated Aug 20, 2026Quarterly Revenue Growth
-66.60%vs Biotechnology peers
Gross Profit (TTM)
701.89MKRW505.75K · vs all stocks (USD)
EBITDA (TTM)
-8.67BKRW-6.25M · vs all stocks (USD)
Net Income (TTM)
-10.12BKRW-7.29M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
-66.10%vs Biotechnology peers
Operating Cash Flow (TTM)
-4.07BKRW-2.93M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-8.40BKRW-6.06M · vs all stocks (USD)
Payout Ratio
0.00%vs Biotechnology peers
Revenue
2.17BKRWFY2025 · Dec 31, 2025Gross Profit
2.17BKRWFY2025 · Dec 31, 2025Operating Income
-7.26BKRW-5.23M · vs all stocks (USD)
Pre-tax Income
-9.73BKRWFY2025 · Dec 31, 2025Net Income
-9.73BKRWFY2025 · Dec 31, 2025EBIT
-9.11BKRWFY2025 · Dec 31, 2025EBITDA (Income Statement)
-4.00BKRWFY2025 · Dec 31, 2025Research & Development
4.02BKRWFY2025 · Dec 31, 2025Selling, General & Administrative
754.73MKRWFY2025 · Dec 31, 2025Other Operating Expenses
116.76MKRWFY2025 · Dec 31, 2025Non-operating Interest Income
3.33BKRWFY2025 · Dec 31, 2025Non-operating Interest Expense
618.94MKRWFY2025 · Dec 31, 2025Net Income from Continuing Operations
-9.73BKRWFY2025 · Dec 31, 2025Operating Cash Flow
-11.21BKRWFY2025 · Dec 31, 2025Free Cash Flow
-11.50BKRWFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
7.07BKRWFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-9.73BKRWFY2025 · Dec 31, 2025Stock-based Compensation
1.14BKRWFY2025 · Dec 31, 2025Other Non-cash Items
-2.73BKRWFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
114.63MKRWFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-2.37MKRWFY2025 · Dec 31, 2025Capital Expenditures
-287.84MKRWFY2025 · Dec 31, 2025Purchase of Investments
-98.89BKRWFY2025 · Dec 31, 2025Sale of Investments
104.79BKRWFY2025 · Dec 31, 2025Other Investing Activity
113.98KKRWFY2025 · Dec 31, 2025Net Investing Cash Flow
5.61BKRWFY2025 · Dec 31, 2025Other Financing Charges
-10.34MKRWFY2025 · Dec 31, 2025Net Financing Cash Flow
1.84BKRWFY2025 · Dec 31, 2025Shares Outstanding
23.34MSharesUpdated Aug 20, 2026Float Shares
17.81MSharesUpdated Aug 20, 2026% Held by Insiders
16.51%vs all stocks
% Held by Institutions
6.93%vs all stocks
Total Cash (MRQ)
82.94BKRW59.76M · vs all stocks (USD)
Total Cash per Share (MRQ)
3.56KKRWUpdated Aug 20, 2026Total Debt (MRQ)
440.09MKRW317.11K · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.0045xvs Biotechnology peers
Current Ratio (MRQ)
110.34xvs Biotechnology peers
Book Value per Share (MRQ)
4.20KKRWUpdated Aug 20, 2026Total Assets
97.12BKRW69.98M · vs all stocks (USD)
Total Current Assets
94.71BKRWFY2025 · Dec 31, 2025Total Liabilities
803.77MKRWFY2025 · Dec 31, 2025Total Non-current Assets
2.41BKRWFY2025 · Dec 31, 2025Total Non-current Liabilities
262.25MKRWFY2025 · Dec 31, 2025Total Current Liabilities
541.52MKRWFY2025 · Dec 31, 2025Cash Equivalents
7.07BKRWFY2025 · Dec 31, 2025Cash & Cash Equivalents
7.07BKRWFY2025 · Dec 31, 2025Other Short-term Investments
85.70BKRWFY2025 · Dec 31, 2025Short-term Debt
264.65MKRWFY2025 · Dec 31, 2025Other Current Liabilities
1.03KKRWFY2025 · Dec 31, 2025Long-term Debt
233.34MKRWFY2025 · Dec 31, 2025Other Non-current Liabilities
10.00KRWFY2025 · Dec 31, 2025Common Stock (Book)
23.21BKRWFY2025 · Dec 31, 2025Retained Earnings
-82.08BKRWFY2025 · Dec 31, 2025Total Shareholders' Equity
96.32BKRW69.40M · vs all stocks (USD)
52-Week Low
19.37KKRWUpdated Aug 20, 202652-Week High
76.70KKRWUpdated Aug 20, 202652-Week Change
0.95%vs all stocks
Beta
1.66xvs all stocks
50-Day MA
31.58KKRWUpdated Aug 20, 2026200-Day MA
48.51KKRWUpdated Aug 20, 2026Avg 10-Day Volume
214.28KSharesUpdated Aug 20, 2026Avg 30-Day Volume
195.16KSharesUpdated Aug 20, 2026Diluted EPS (TTM)
-429.00KRWUpdated Aug 20, 20265 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
Liquidity Ratios Elevated
It can cover near-term bills from cash alone, not just from inventory.
Reads
Low-Leverage Liquidity Configuration
Cash on hand covers most or all of its debt, and its equity share of assets is high for its industry.
Reads
How does this company use capital?
Industry-Benchmarked ROA and Margin Elevated
Returns and margins have sat in the top of its industry across five years.
Reads
Where is this company structurally exposed?
Ulcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
It sits well below its peak, and the fall has been both deep and long.
Partial Recovery After Sharp Decline
A weak, thin-volume bounce inside a decline that is still far from recovered.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Gross margin is 100%, higher than 95% of its Biotechnology peers (median 67.1%)Significant
Gross margin: 1.00Industry median: 0.67Industry P95: 1.00Peers compared: 261
Current ratio is 110.34×, higher than 95% of its Biotechnology peers (median 5.64×)Significant
Current ratio: 110.338Industry median: 5.64Industry P95: 23.02Peers compared: 261
Structural Tensions
High gross margins eroded by operating costsNotable
Gross Margin: 1.00Profit Margin: 0.00
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Revenue is $522,658, lower than 95% of all stocks globallySignificant
Revenue (USD): 522,658.208Global P5: 30,274,777.221
Companies that share the same coordination system — how they create, deliver, or capture value.
Zhejiang Shengda Bio-Pharm Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
X4 Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
Zhejiang East-Asia Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Shandong Sito Biotechnology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Zhejiang Tailin Bioengineering Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Suzhou Fushilai Pharmaceutical Co. Ltd.
Tier 1ProductionApproval-Gated PipelineFlowRule
Shanghai Universal Biotech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Bionote Inc.
Tier 1ProductionApproval-Gated PipelineRule
Zhejiang Zhenyuan Co., Ltd.
Tier 1ProductionApproval-Gated PipelineFlowRule
Hainan Huluwa Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Juneway Electronic Technology Co.
5 interpretationsPartial Recovery After Sharp DeclineUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility ElevatedLiquidity Ratios ElevatedIndustry-Benchmarked ROA and Margin ElevatedLow-Leverage Liquidity Configuration
Shenzhen JDD Tech New Material Co., Ltd.
5 interpretationsPartial Recovery After Sharp DeclineUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility ElevatedLiquidity Ratios ElevatedIndustry-Benchmarked ROA and Margin ElevatedLow-Leverage Liquidity Configuration
Hangzhou XZB Tech Co., Ltd.
5 interpretationsPartial Recovery After Sharp DeclineUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility ElevatedLiquidity Ratios ElevatedIndustry-Benchmarked ROA and Margin ElevatedLow-Leverage Liquidity Configuration